v3.24.1.1.u2
Segment Information (Tables)
 12 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule Of Company Revenue and Adjusted EBITDA by Segment
The Company’s revenue and Adjusted EBITDA by segment is as follows:
Year Ended March 31,
202420232022
(in thousands)
Segment Revenue: (1)
Consumer and Research Services$219,638 $299,489 $271,893 
Total revenue$219,638 $299,489 $271,893 
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA$(36,769)$(17,997)$(30,112)
Therapeutics Adjusted EBITDA(91,025)(88,503)(76,944)
Unallocated Corporate (2)
(48,002)(54,801)(43,684)
Total Adjusted EBITDA$(175,796)$(161,301)$(150,740)
Reconciliation of net loss to Adjusted EBITDA:
Net loss$(666,704)$(311,656)$(217,490)
Adjustments
Interest income, net(14,331)(9,676)(277)
Other (income) expense, net(506)93 83 
Change in fair value of warrant liabilities— — (32,989)
Provision for (benefit from) income taxes73 (2,772)(3,480)
Depreciation and amortization18,033 20,239 18,899 
Amortization of acquired intangible assets11,448 16,486 7,269 
Impairment of acquired intangible assets— 9,968 — 
Stock-based compensation expense120,209 116,017 57,933 
Acquisition-related costs (3)
— — 9,362 
Litigation settlement, net (4)
98 — 9,950 
Loss on disposition of Lemonaid Health Limited and transaction-related costs (5)
2,375 — — 
Goodwill impairment (6)
351,744 — — 
Cybersecurity incident expenses, net of probable insurance recoveries (7)
1,765 — — 
Total Adjusted EBITDA$(175,796)$(161,301)$(150,740)
(1)All product and service revenue is associated with the Consumer and Research Services segment and there was no Therapeutics revenue for the fiscal years ended March 31, 2024, 2023 and 2022.
(2)Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.
(3)For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees.
(4)Litigation settlement, net is litigation cost net of probable insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.
(5)Refer to Note 19, “Disposition of Subsidiary” for additional information.
(6)Refer to Note 10, “Balance Sheet Components — Goodwill” for additional information.
(7)Refer to Note 13, “Commitments and Contingencies — Cybersecurity Incident” for additional information.
Summary of Customers Accounting for 10% or More of Segment Revenues
Customers accounting for 10% or more of segment revenues were as follows:
Year Ended March 31,
202420232022
(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C (1) (2)
$48,325 22 %$65,721 22 %$53,875 20 %
Customer B (3)
$11,753 5 %$47,448 16 %$46,064 17 %
(1)Customer C is a reseller
(2)Customer C revenues are primarily in the United States.
(3)Customer B revenues are in the U.K.